Scopia Capital Management

YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients through immunotherapies. YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies. To further improve its bispecific antibodies, the company collaborates on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. YmAbs' treatments claims to potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA approval.

ZALORA is an e-commerce platform that specializes in fashion and footwear, offering a wide range of products for both men and women. Launched in March 2012 and based in Ho Chi Minh City, Vietnam, ZALORA features items from well-known brands such as Mango, Nike, Puma, Calvin Klein, and Levi's. The platform allows users to browse and purchase clothing, shoes, accessories, and beauty products online. In addition to its retail offerings, ZALORA provides fashion tips, advice, and an online magazine to enhance the shopping experience. The company received $112 million in private equity funding in December 2013, further solidifying its position in the online fashion retail market.